ADA and triple-A syndrome: Sejournet et al (8) and Pichi et al (10) reported that AAA formation, low ADA levels together with therapy failure brought about increased ADA dosing frequency, an increased dose and intraclass or interclass treatment switching, suggesting that TDM may be useful in determining treatment adjustment.